Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 292

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 292
---
 not intended to represent an assessment of claim limitations or claim scope. Included in the portfolio
are seven (7) patent families.

On February 11, 2014, the United States Patent
and Trademark Office (“USPTO”) issued to DiamiR U.S. Patent No. 8,648,017, entitled “Methods of Using Small RNA from
Bodily Fluids for Diagnosis and Monitoring of Neurodegenerative Diseases.” The patent, which is set to expire on November 4, 2030,
claims the use of methods developed by DiamiR for detecting neurite destruction and synapse loss, associated with a neuronal pathology,
prior to neuronal cell death as well as methods for monitoring changes in neurite destruction and synapse loss associated with development
of a neuronal pathology and monitoring the effect of a treatment on neurite destruction and synapse loss in a subject suffering from a
neuronal pathology. In addition, foreign counterparts to the U.S. patent have been granted in Canada, Switzerland, Germany, Spain, France,
United Kingdom, Ireland and Italy.

On October 31, 2017, the USPTO issued to DiamiR
U.S. Patent No.9,803,242, entitled “miRNA - Based Universal Screening Test (“UST”).” The patent, which is set
to expire on December 26, 2032, claims the use of methods developed by DiamiR for selecting subjects for administering one or more disease-specific
diagnostic tests to identify a specific pathology in the gastrointestinal (GI) system and/or the respiratory system and/or the nervous
system (and further determine if such pathology is an inflammation or cancer). On November 12, 2019, the USPTO issued to DiamiR a second
U.S. Patent No. 10,472,681 with related claims directed to selecting subjects for administering one or more disease-specific diagnostic
tests to identify a specific pathology in lung or in a gastrointestinal (GI) organ, which is set to expire on April 18, 2032. In addition,
foreign counterparts to the U.S. patents have been granted in Australia, Canada, China, Switzerland (2), Germany (2), Spain, France (2),
United Kingdom (2), Ireland, Italy, and Japan.

On January 31, 2017, the USPTO issued to DiamiR
U.S. Patent No.9,556,487, entitled “Methods of using miRNA from bodily fluids